EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG

View source ↗

Summary

The European Medicines Agency authorised Kefdensis, a denosumab medicine by STADA Arzneimittel AG, for osteoporosis indications including postmenopausal osteopo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Kefdensis (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal. MAH: Stada Arzneimittel AG. Decision date: 04/03/2026